03
Oct
A pharmaceutical company's attempt to win approval for a new Alzheimer's treatment, simufilam, continues amid a flurry of controversy and regulatory challenges. Recent investigations have cast doubt on the basic studies supporting simufilam. These concerns increased when scientific journals retracted several studies and key figures at Cassava Sciences, the drug's sponsor, resigned. Despite these setbacks, in September the Securities and Exchange Commission (SEC) accused Cassava Sciences of disseminating misleading data about their clinical trials. However, the company settled these charges by paying $40 million, without admitting any guilt. Interestingly, simufilam is still undergoing Phase 3 trials, involving more than 1,900…